Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
<i>O</i>(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation is a high predictive factor for therapy results of temozolomide in patients with glioma.
|
31422371 |
2020 |
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Conventional MRI radiomics models are reliable for predicting the MGMT promoter methylation status in LGG patients.
|
31704598 |
2019 |
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The present study aimed to reveal the key genes implicated in MGMT promoter methylation in patients with glioma.
|
30535433 |
2019 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The positive rate of MGMT autoantibody to 20 peptides in glioma groups is compared with healthy individuals, the positive rate of MGMT-02 (45%), MGMT-04 (27%), MGMT-07 (21%), MGMT-10 (13%), and MGMT-18 (24%) were significantly elevated in patients with glioma.
|
31210005 |
2019 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>FoxD2-AS1</i> is a prognostic factor in glioma and promotes temozolomide resistance in a O<sup>6</sup>-methylguanine-DNA methyltransferase-dependent manner.
|
31680769 |
2019 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the relationship between SWI features and glioma grades, and the expression of key molecular markers isocitrate dehydrogenase 1 (IDH1), O-6-methylguanine-DNA methyltransferase (MGMT), and 1p19q.
|
31745161 |
2019 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that the MGMT expression was effectively downregulated by 20(S)-Rg3 via the Wnt/β-catenin pathway in glioma cell lines, and TMZ resistance was significantly reversed by 20(S)-Rg3.
|
30431207 |
2019 |
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Then, we also analyzed the impact of TERT promoter mutations, PTEN deletion, EGFR amplification and MGMT promoter methylation in diagnosis, prognosis and response to therapy in glioma molecular subgroup.
|
31623593 |
2019 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioma therapeutic resistance to alkylating chemotherapy is mediated via O6-methylguanine-DNA methyltransferase (MGMT).
|
30500933 |
2019 |
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
This study aimed to build a radiomics signature based on <sup>18</sup>F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for noninvasive measurement of the MGMT promoter methylation status in glioma.
|
31426864 |
2019 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This article gives an updated understanding of the pathogenesis and mechanisms of resistance of glioma via discussion of 4 molecular and genetic markers: MGMT, <i>IDH</i>, 1p/19q, and <i>TERT</i>.
|
30760635 |
2019 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Resveratrol sensitized TMZ-induced glioma cell apoptosis by repressing the activation of the Wnt signaling pathway and downregulating MGMT expression, which may confer new thoughts to the chemotherapy of glioma.
|
30317578 |
2019 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MGMT CpG heterogeneity was investigated in 213 glioma patients in two tested cohorts: cohort A in which CpGs 75-82 were tested and cohort B in which CpGs 72-78 were tested.
|
30291347 |
2019 |
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Our data have shown the absence of MGMT promoter methylation in H3K27M mutant thalamic glioma, validating it as a hallmark of H3K27M mutant gliomas.
|
30885860 |
2019 |
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The objective of this study is to assess the real impact of Io MRI in O-6-methylguanine-DNA methyltransferase and non-O-6-methylguanine-DNA methyltransferase methylated glioma surgery.
|
29309978 |
2018 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
APTw characteristics could be promising imaging markers by which to predict IHC MGMT expression in primary low- and high-grade gliomas preoperatively and noninvasively.
|
29803064 |
2018 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cells and xenografts derived from newly diagnosed MGMT methylated high-grade gliomas were sensitive to TMZ while those derived from unmethylated and recurrent gliomas were typically resistant.
|
30153289 |
2018 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sixty three cases of glioma were evaluated for MGMT promoter methylation by methylation-specific PCR (MS-PCR) and protein expression by immunostaining (IHC).
|
29712977 |
2018 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, VPA may also promote the methylation of the MGMT promoter to silence MGMT expression in glioma cells, which may be an important mechanism through which VPA enhances the efficacy of TMZ and ACNU in targeting glioma stem cells.
|
29805689 |
2018 |
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
|
29733378 |
2018 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, transferrin nanoparticles encapsulating temozolomide have the potential of a promising anti-tumor strategy against glioma of the O6-methylguanine-DNA-methyltransferase gene promoter methylation.
|
29088799 |
2017 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that glioma susceptibility is associated with rs1799782 and rs25487 of X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1), rs1805377 of XRCC4, rs1800067 of excision repair cross-complementing rodent repair deficiency complementation group 4 (ERCC4) and rs3212986 of ERCC1 in Asian population, and rs12917 of O-6-methylguanine-DNA methyltransferase (MGMT) and rs1136410 of poly(ADP-ribose) polymerase 1 (PARP1) in Caucasian population.
|
27055523 |
2017 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Active MGMT might have a protective role in LGG tumors, enabling evolution to severe malignancy.
|
28575062 |
2017 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although methylguanine-DNA-methyltransferase (MGMT) plays an important role in resistance to temozolomide (TMZ) in glioma, 40% of gliomas with MGMT inactivation are still resistant to TMZ.The underlying mechanism is not clear.
|
28185110 |
2017 |
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
|
28436299 |
2017 |